The findings of a study presented a year and a half ago reflect an increased risk of heart defects in infants whose mothers took the medication during pregnancy, which may prompt more Zofran lawsuits in the future.
The results were published in August 2013 at a meeting of the International Society of Pharmacoepidemiology, and revealed vital information related to the drug’s use in pregnant women. According to research taken from a Danish patient registry, a two-fold increase in Zofran heart defects was found in babies born to women who took the medication during the first trimester. 4.7 percent of women who took it during this period, which is the most crucial for fetal development, had a baby with a congenital malformation. 3.5 percent of pregnancies resulted in a birth defect without exposure to Zofran, the study found. 900,000 pregnancies occurring between 1997 and 2010 were included in the research, 1,248 of which involving Zofran in the first trimester.
In 2012, a study from the Center for Birth Defects Research and Prevention relayed similar results. Among other things, researchers found a two-fold increased risk for cleft palates in Zofran babies who were exposed in the first trimester. 9,000 pregnancies were included in the study, which took data from the National Birth Defects Prevention Study. In addition to these findings, research has also looked at the risk for Zofran kidney and heart defects, as well as several brain malformations. Just this past January, a case study released by the Pediatric Emergency Care linked the medication to an increased risk for life-threatening heart problems in two deaths that occurred in children who were exposed to the drug. The probe involved an otherwise healthy 10-year-old-boy who was admitted to the emergency room for gastroenteritis symptoms, and an 86-year old infant who came in with similar issues. Both developed a faster-than-normal heart rate and became unresponsive thereafter, researchers found.
A look into Health Canada’s adverse event report database also found 20 complaint reports from 2012 alone, which may have noted Zofran brain defects.
If you or someone you know had a child with Zofran birth defects following use of the medication, the time is now to call an attorney who can be sensitive to your situation and guide you towards filing a complaint against the drug’s manufacturer, GlaxoSmithKline. Call our Firm today at .